Evolution of the Average Target: BioNTech SE

Evolution of the Target Price: BioNTech SE

Changes in Analyst Recommendations: BioNTech SE

2aeded3bc7c00ec6e587061.NkCNt1r_A6wNERo1L-cjAZmUzMPJSVaN4CDO4tL_L4o.BTr77WqdbMNgUCJZHIlNZvjk-Jr7JTPXjFSAlrDNe_hCd9TZaIha22VzVw~835b4a9e67ddf5af3317ef52229a7ca8
08-28 Germany's DAX Index Extends Gains; BioNTech Tumbles After Scrapping Cancer Vaccine Trial MT
08-26 BioNTech SE : Deutsche Bank reiterates its Buy rating ZD
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-20 BioNTech SE : Jefferies keeps its Buy rating ZD
08-05 Berenberg Bank Adjusts BioNTech SE Price Target to $132 From $140, Maintains Buy Rating MT
08-05 BIONTECH : Berenberg reiterates its Buy rating ZD
08-04 BIONTECH : Gets a Buy rating from Jefferies ZD
08-04 BIONTECH : Bernstein sticks Neutral ZD
08-04 BioNTech: Q2 miss, followed by a sales guidance downgrade Alphavalue
08-04 Wall Street Bets on the Magnificent Seven Again Zonebourse
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-08 Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating MT
06-01 BIONTECH : Buy rating from Jefferies ZD
05-27 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
05-27 BIONTECH : From Neutral to Buy by UBS ZD
05-27 UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117 MT
05-22 Bernstein Initiates Coverage on BioNTech With Market Perform Rating MT
05-12 Berenberg Still Confident on BioNTech Despite Lower Price Target Zonebourse
05-12 Berenberg Lowers Price Target on BioNTech to $140 From $155, Keeps Buy Rating MT
05-12 BIONTECH : Receives a Buy rating from Berenberg ZD
05-05 BioNTech: Though Q1 operations missed expectations, 2026 guidance remained unchanged Alphavalue
04-13 BIONTECH : Berenberg reaffirms its Buy rating ZD
03-25 BIONTECH : Jefferies reiterates its Buy rating ZD
03-17 BIONTECH : Deutsche Bank maintains a Buy rating ZD
03-12 Goldman Sachs Sees a Buying Opportunity in BioNTech Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+8.86%
+14.99%
- +6.36%
+64.91%
+9.22%
-13.98%
+11.23%
+17.17%
-4.09%
+24.37%
Average +13.90%
Weighted average by Cap. +13.84%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
87.96EUR
Average target price
103.67EUR
Spread / Average Target
+17.86%
High Price Target
124.37EUR
Spread / Highest target
+41.40%
Low Price Target
65.19EUR
Spread / Lowest Target
-25.88%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. BNTX Stock
  4. Consensus BioNTech SE